Clinical trial
Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable…
NCT00282100 · Tan Tock Seng Hospital, Other · Unknown status
Key facts
| NCT number | NCT00282100 |
|---|---|
| Title | Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma |
| Official title | A Pilot Study of Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma |
| Lead sponsor | Tan Tock Seng Hospital, Other |
| Collaborators | Singapore Cancer Syndicate. AstraZeneca Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Liver Cancer |
| Intervention type | Drug |
| Interventions | Gefetinib (Iressa) |
| Enrollment | 40 |
| Start date | Dec 1, 2005 |
| Primary completion | Sep 1, 2019 |
| Completion | Sep 1, 2019 |
| First posted | Jan 25, 2006 |
| Last update posted | Apr 16, 2019 |
| Countries | Singapore |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: